Trinomab’s IPO Application Successfully Passes Review
On April 3, 2026, Zhuhai Trinomab Biopharmaceutical Co., Ltd. (hereafter referred to as "Trinomab") successfully secured approval from the Listing Review Committee of the Shanghai Stock Exchange (SSE) for its initial public offering (IPO) on the Science and Technology Innovation Board (STAR Market). This milestone marks a significant leap forward for Trinomab, culminating years of dedicated cultivation in the innovative biopharmaceutical sector and unwavering commitment to research and development (R&D).
(Source: Screenshot from the official website of the Shanghai Stock Exchange)
Dual Core Products Lead the Way，Hillhouse Empowers to Consolidate Innovation Foundation
Trinomab specializes in development of fully human monoclonal antibodies as therpeutics, anchored by its proprietary HitmAb High-Throughput Fully Human Monoclonal Antibody R&D Platform, This cutting-edge platform technology has enabled the company to build a differentiated and robust product pipeline, headlined by two flagship products. Its lead product, Siltartoxatug Injection, stands as the world’s first recombinant anti-tetanus toxin monoclonal antibody. Approved for commercial launch in February 2025, it has earned prestigious designations including Breakthrough Therapy Designation and Priority Review from the China National Medical Products Administration (NMPA) as well as Fast Track designation from U.S. FDA. In December 2025, it was successfully included in China’s National Reimbursement Drug List (NRDL), a pivotal step that will significantly accelerate its market penetration and improve accessibility for patients across the country.
The company’s second core product， Retavibart Injection (recombinant long-acting fully human anti-RSV monoclonal antibody), aims for a critical unmet medical need in prevention and control of respiratory syncytial virus (RSV) infections in children. RSV infection is a leading cause of severe lower respiratory tract diseases in children. Retavibart Injection targets pre-fusion F (Pre-F) protein of the virus which is critical component for the virus entering host cells. Clinical trials of Retavibart Injection have demonstrated its favorable protective efficacy and safety profile. New Drug Application (NDA) of Retavibart Injection has been accepted with Priority Review designation by NMPA. If approved, Retavibart Injection has potential to transform RSV prevention for children in China and worldwide. The breakthrough progress of these two core products has paved solid clinical and commercial validation in supporting Trinomab’s qualification to meet the fifth set of listing criteria on the STAR Market.
Beyond its product strengths, Trinomab benefits from strategic backing by the Zhuhai Hillhouse Private Fund Management Co., Ltd. (hereinafter referred to as “Zhuhai Hillhouse”), Hillhouse’s long-term confidence in Trinomab’s innovation capabilities has translated into comprehensive support, providing professional capital and industrial resources to fuel R&D advancement and market expansion. The successful IPO review stands as a testament to value of this deep partnership in driving innovation in the biopharmaceutical sector.
Embarking on a New Capital Journey to Accelerate the Translation of Innovative Achievements
Trinomab plans to raise RMB 1.5 billion through this IPO, with funds earmarked primarily for three areas: advancing new drug R&D initiatives, expanding its antibody production bases to meet commercial demand, and supplementing working capital to support operational scalability. By effectively leveraging the power of the capital market, the company aims to strengthen its core technology platform, enrich its product pipeline, enhance production efficiency, and accelerate the translation of innovative research from the laboratory to the clinic and from the market to patients. This will not only drive the company’s growth but also enable it to deliver more life-changing treatments to patients worldwide, solidifying its position in leading global blood product replacement therapies with fully human monoclonal antibody technology.
